Omilancor Sales Forecast, and Market Size Analysis - 2034

Key Factors Driving Omilancor Growth

1. First-in-class LANCL2 agonist mechanism (high differentiation)

• Omilancor is a first-in-class activator of LANCL2, a novel immunometabolic pathway regulating inflammation.
• It enhances regulatory T-cell (Treg) function and suppresses pro-inflammatory signaling.
• Differentiates from existing biologics (anti-TNF, JAK inhibitors)
• Enables potential best-in-class positioning in inflammatory diseases

2. Strong clinical efficacy signals in ulcerative colitis (UC)

• Phase II data show:
• ~30.4% clinical remission vs 3.7% placebo (Δ ~26.7%, p=0.01)
• Additional Phase II study:
• Demonstrated clinical remission endpoints over 12 weeks with once-daily dosing
• Clear proof-of-concept efficacy → key value inflection point
• Supports advancement toward late-stage trials

3. Favorable safety and tolerability profile

• Phase I:
• Well tolerated up to ~7000-7500 mg/day without dose-limiting toxicities
• Phase II:
• No major adverse event trends vs placebo
• Strong safety profile vs biologics/immunosuppressants
• Enables chronic long-term use → recurring revenue potential

4. Broad multi-indication potential (IBD + dermatology + beyond)

• Clinical focus:
• Ulcerative colitis (UC), Crohn’s disease (CD)
• Preclinical/early evidence:
• Psoriasis (topical efficacy)
• Potential in intervertebral disc degeneration and inflammatory diseases
• Multi-indication expansion → large commercial upside
• Supports franchise-level development

5. Large unmet need in inflammatory bowel disease (IBD)

• IBD (UC + CD) remains:
• Chronic, relapsing disease
• Many patients fail biologics or lose response over time
• Omilancor offers:
• Novel mechanism + gut-restricted activity, targeting inflammation locally
• Addresses significant unmet need in moderate-to-severe IBD
• Potential for rapid adoption if Phase III confirms efficacy

Omilancor Recent Developments

In 2023, NImmune reported that a Phase II trial met its primary endpoint. In an active disease population, Omilancor induced clinical remission in 30.4% of patients vs. 3.7% for placebo (P = 0.01). It demonstrated endoscopic remission (41.7% vs 18.6%) and a benign safety profile.  
“Omilancor Sales Forecast, and Market Size Analysis - 2034” report provides comprehensive insights of Omilancor for potential indication like Ulcerative colitis and Crohn’s disease in the 7MM. A detailed picture of Omilancor’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the Omilancor for potential indications. The Omilancor market report provides insights about Omilancor’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Omilancor performance, future market assessments inclusive of the Omilancor market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Omilancor sales forecasts, along with factors driving its market.

Omilancor Drug Summary

Omilancor is an investigational, orally administered small molecule developed by Landos Biopharma that targets the lanthionine synthetase C-like protein 2 (LANCL2) pathway, a novel immunometabolic regulator involved in maintaining immune homeostasis and epithelial barrier function. By activating LANCL2, omilancor modulates inflammatory responses through enhancement of regulatory immune pathways rather than direct cytokine inhibition, aiming to reduce inflammation while preserving normal immune function. It is being studied primarily for the treatment of ulcerative colitis, where early-phase clinical trials have demonstrated improvements in clinical remission, mucosal healing, and biomarkers of inflammation, along with a favorable safety and tolerability profile. Administered as an oral therapy, omilancor offers potential advantages in convenience and a differentiated mechanism compared to biologics and JAK inhibitors, though it remains in clinical development and has not yet received regulatory approval. The report provides Omilancor’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Omilancor Market Report

The report provides insights into:

• A comprehensive product overview including the Omilancor MoA, description, dosage and administration, research and development activities in potential indication like Ulcerative colitis and Crohn’s disease.
• Elaborated details on Omilancor regulatory milestones and other development activities have been provided in Omilancor market report.
• The report also highlights Omilancor‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The Omilancor market report also covers the patents information, generic entry and impact on cost cut.
• The Omilancor market report contains current and forecasted Omilancor sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Omilancor market report also features the SWOT analysis with analyst views for Omilancor in potential indications.

Methodology

The Omilancor market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Omilancor Analytical Perspective

• In-depth Omilancor Market Assessment

This Omilancor sales market forecast report provides a detailed market assessment of Omilancor for potential indication like Ulcerative colitis and Crohn’s disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Omilancor sales data uptil 2034.

• Omilancor Clinical Assessment

The Omilancor market report provides the clinical trials information of Omilancor for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Omilancor Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Omilancor Market Potential & Revenue Forecast

• Projected market size for the Omilancor and its key indications
• Estimated Omilancor sales potential (Omilancor peak sales forecasts)
• Omilancor Pricing strategies and reimbursement landscape

Omilancor Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Omilancor Market positioning compared to existing treatments
• Omilancor Strengths & weaknesses relative to competitors

Omilancor Regulatory & Commercial Milestones

• Omilancor Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Omilancor Clinical Differentiation

• Omilancor Efficacy & safety advantages over existing drugs
• Omilancor Unique selling points

Omilancor Market Report Highlights

• In the coming years, the Omilancor market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Omilancor companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Omilancor’s dominance.
• Other emerging products for Ulcerative colitis and Crohn’s disease are expected to give tough market competition to Omilancor and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Omilancor in potential indications.
• Analyse Omilancor cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Omilancor sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Omilancor in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of Omilancor? How strong is Omilancor’s clinical and commercial performance?
• What is Omilancor’s clinical trial status in each individual indications such as Ulcerative colitis and Crohn’s disease and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Omilancor Manufacturers?
• What are the key designations that have been granted to Omilancor for potential indications? How are they going to impact Omilancor’s penetration in various geographies?
• What is the current and forecasted Omilancor market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Omilancor in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Omilancor for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is Omilancor? What is the duration of therapy and what are the geographical variations in cost per patient?

This product will be delivered within 2 business days.